Cargando…

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nyakas, M., Aamdal, E., Jacobsen, K. D., Guren, T. K., Aamdal, S., Hagene, K. T., Brunsvig, P., Yndestad, A., Halvorsen, B., Tasken, K. A., Aukrust, P., Mælandsmo, G. M., Ueland, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591141/ https://www.ncbi.nlm.nih.gov/pubmed/30821848 http://dx.doi.org/10.1111/cei.13283

Ejemplares similares

Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
por: Aamdal, E., et al.
Publicado: (2022)

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
por: Aamdal, Elin, et al.
Publicado: (2021)

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
por: Sioud, Mouldy, et al.
Publicado: (2016)

Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
por: Berg, Janna, et al.
Publicado: (2018)

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022)

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
por: Brunsvig, Paal F., et al.
Publicado: (2020)

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022)

Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
por: Andersson, Y, et al.
Publicado: (2015)

Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
por: Fr Brunsvig, Paal, et al.
Publicado: (2007)

Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma
por: Chu, Michael P., et al.
Publicado: (2020)

Assessing quality of life in a randomized clinical trial: Correcting for missing data
por: Gunnes, Nina, et al.
Publicado: (2009)

Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease.
por: Gundersen, S., et al.
Publicado: (1987)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
por: Piérard, Gérald E., et al.
Publicado: (2012)

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
por: Bostwick, A Doran, et al.
Publicado: (2015)

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
por: Hamid, Omid, et al.
Publicado: (2011)

High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection
por: Andersen, Anders, et al.
Publicado: (2006)

Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma
por: Krecké, Nathalie, et al.
Publicado: (2016)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
por: Mullally, W. J., et al.
Publicado: (2022)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
por: Formozo, A. A., et al.
Publicado: (2021)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma
por: Andrews, Stephanie, et al.
Publicado: (2012)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics
por: Rossfeld, Kara, et al.
Publicado: (2017)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience
por: Pacholczak-Madej, Renata, et al.
Publicado: (2022)

Acute visual loss after ipilimumab treatment for metastatic melanoma
por: Wilson, Melissa A., et al.
Publicado: (2016)

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
por: Chmielowski, Bartosz
Publicado: (2013)

Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma
por: Montes, Vera, et al.
Publicado: (2018)

Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
por: Hanley, T, et al.
Publicado: (2018)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Ipilimumab and Cancer Immunotherapy: A New Hope for Advanced Stage Melanoma
por: Mansh, Matthew
Publicado: (2011)

The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
por: Daly, Louise E, et al.
Publicado: (2017)

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
por: Ferrucci, P F, et al.
Publicado: (2015)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients.
por: Tefre, T., et al.
Publicado: (1990)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i5d2ic7fl8ubk7s3eiv18jcefb